Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Rating Lowered by StockNews.com

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Thursday.

Several other brokerages also recently issued reports on FMS. Berenberg Bank lowered their price target on Fresenius Medical Care AG & Co. KGaA from €84.90 ($89.37) to €83.40 ($87.79) in a report on Thursday, March 17th. JPMorgan Chase & Co. increased their price target on Fresenius Medical Care AG & Co. KGaA from €48.70 ($51.26) to €51.00 ($53.68) and gave the company an “underweight” rating in a report on Thursday, May 5th. Oddo Bhf upgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “outperform” rating and set a €72.00 ($75.79) price target for the company in a report on Tuesday, March 1st. Truist Financial lowered their target price on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating for the company in a research note on Wednesday. Finally, Societe Generale lowered their target price on Fresenius Medical Care AG & Co. KGaA from €61.00 ($64.21) to €57.00 ($60.00) in a research note on Friday, February 25th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $52.09.

NYSE FMS traded up $0.24 during trading hours on Thursday, hitting $24.17. The company had a trading volume of 1,228,796 shares, compared to its average volume of 550,739. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $23.29 and a fifty-two week high of $42.13. The company has a market capitalization of $14.16 billion, a price-to-earnings ratio of 13.81, a P/E/G ratio of 0.98 and a beta of 1.17. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.26 and a quick ratio of 0.93. The firm’s 50 day moving average is $29.61 and its 200 day moving average is $31.61.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.08. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.99% and a net margin of 4.91%. The firm had revenue of $5.10 billion during the quarter, compared to the consensus estimate of $4.97 billion. On average, equities analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.93 EPS for the current year.

Large investors have recently bought and sold shares of the stock. Commonwealth Equity Services LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 6.4% in the fourth quarter. Commonwealth Equity Services LLC now owns 13,583 shares of the company’s stock worth $440,000 after purchasing an additional 817 shares in the last quarter. Atlas Capital Advisors LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 27.1% in the fourth quarter. Atlas Capital Advisors LLC now owns 9,266 shares of the company’s stock worth $301,000 after purchasing an additional 1,973 shares in the last quarter. UMB Bank N A MO acquired a new position in Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth about $192,000. Cacti Asset Management LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 35.8% in the first quarter. Cacti Asset Management LLC now owns 36,000 shares of the company’s stock worth $1,212,000 after purchasing an additional 9,500 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 283.2% in the fourth quarter. Legacy Wealth Asset Management LLC now owns 36,892 shares of the company’s stock worth $1,198,000 after purchasing an additional 27,264 shares in the last quarter. Institutional investors and hedge funds own 4.73% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile (Get Rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Recommended Stories